Choices on Biosecurity

This issue of The Scientist focuses on biosecurity. More specifically, it deals with the handling and detection of select agents, a catalog of about 80 bacteria, viruses, fungi, and toxins that US authorities have identified as particularly high-risk. See page 12 for a primer.Select agents divide the US research community like few other topics. Regulations for their transport and handling are considered either prudent or draconian, a minor inconvenience or a grave impediment, depending on who yo

Written byRichard Gallagher
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

This issue of The Scientist focuses on biosecurity. More specifically, it deals with the handling and detection of select agents, a catalog of about 80 bacteria, viruses, fungi, and toxins that US authorities have identified as particularly high-risk. See page 12 for a primer.

Select agents divide the US research community like few other topics. Regulations for their transport and handling are considered either prudent or draconian, a minor inconvenience or a grave impediment, depending on who you ask (the article on page 45 could help you make up your mind). And debate is raging over the planned order-of-magnitude increase in the biosafety level (BSL-) 3 and 4 lab space being built to house research on select agents. Why is such capacity needed, and who is going to staff these labs? The opposing arguments are thrashed out on page 48.

There is also discord over research. One area of feverish ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies